1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIDA Funding Opportunities is sponsored by National Institute on Drug Abuse (NIDA). This encompasses a wide range of NIDA-supported funding opportunities for research on the causes, consequences, prevention, and treatment of drug use and addiction, supporting basic science, clinical, and translational research. Specific eligibility varies by individual funding opportunity.
Get alerted about grants like this
Save a search for “National Institute on Drug Abuse (NIDA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
As of October 2025, the NIDA Funding App has been retired. The NIH announcement stating this change can be read here: NOT-OD-25-143 . NIDA Funding Strategy – A review of NIDA’s strategy for funding, based on programmatic priorities.
Notice of Special Interest (NOSI) - Formerly known as Drug Abuse Topics of Special/Continuing Interest (DAT) NIDA Challenges Program – Crowd-sourced opportunities for providing solutions for particular goals. Helping to End Addiction Long-term (HEAL) Initiative – Congressional initiative to address the opioid overdose crisis. NIDA International Program – International research collaboration opportunities on drug abuse and addiction.
See NIDA’s Resources for Grants & Contracts to learn more about applying for a grant and the pre-approval and approval process. Administrative Supplements for Grants & Cooperative Agreements Administrative Supplements for Grants & Cooperative Agreements – Additional funding to an active NIDA grant or cooperative agreement.
Supplemental Information for NOFOs Supplemental Information for NOT-DA-22-064: Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-24-007.
FAQs for Registry of Medical Cannabis Use and Health Outcomes: RFA-DA-23-011 Supplemental Information for NIH Developmental Studies Biospecimen Access Program FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-23-014 Pre-Application Information Webinar for PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders FAQs Regarding Notice of Information: Establishment of a Standard THC Unit to be Used in Research (NOT-DA-21-049) Frequently Asked Questions about NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus RFA-DA-21-009: Pre-Application Webinar and FAQs- Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research - RFA-DA-20-025 FAQs for Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) FAQs for NOT-DA-19-003: HEAL Initiative: Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) Supplemental Information (FAQs) for NIDA Research E-cigarette - PAR-17-156 Supplemental Information (FAQs) for RFA-DA-17-014 and RFA-DA-17-023
Based on current listing details, eligibility includes: Researchers and institutions involved in basic and clinical research related to substance use disorders. Specific eligibility varies by individual funding opportunity. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies by specific opportunity Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This NOFO supports small business concerns (SBCs) to develop technologies for commercialization that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. The goal is to improve outcomes for individuals struggling with SUD by mitigating the influence of social determinants of health and health-related social needs.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA). Supports research projects at the intersection of HIV and substance use, aiming to open new areas of HIV/AIDS research and lead to new avenues for prevention, treatment, and cure of HIV among people who use addictive substances.
NIDA Cutting-Edge Basic Research Awards (CEBRA) is a grant from the National Institute on Drug Abuse (NIDA) that funds high-risk, high-impact basic research in substance use disorders (SUDs) that falls outside current research portfolios. Delivered through the R21 Exploratory/Developmental Research Grant mechanism, CEBRA supports up to $275,000 in direct costs over two years. Projects must be genuinely novel and not incremental extensions of ongoing work; alcohol-only studies are not eligible. Both established SUD researchers and investigators from other disciplines bringing fresh approaches are welcome to apply. Any domestic or foreign institution eligible for NIH funding may submit, with a next deadline of August 2026.